Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.
Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.
Replacement of potassium in the treatment or prevention of hypokalemia,Fluid and electrolyte replenishment,Correction of dehydration and maintenance of fluid balance
Emergency treatment of hypocalcemia,Cardiac resuscitation (e.g., hyperkalemia, calcium channel blocker overdose, beta-blocker overdose),Treatment of hypermagnesemia,Treatment of acute symptomatic hypocalcemic tetany,Off-label: Prevention of hypocalcemia during massive blood transfusion, adjunctive treatment of lead poisoning (calcium EDTA), and treatment of fluoride poisoning
Intravenous administration at a rate not exceeding 10 m Eq/hour of potassium chloride; typical adult dose is 20-40 m Eq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.
Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.
Potassium has a biphasic elimination: distribution half-life ~1 hour, terminal elimination half-life ~12 hours in normal renal function. Clinical context: Half-life extends significantly in renal impairment, requiring dose adjustment.
Rapid distribution half-life ~5-10 min; terminal half-life 3-6 hours due to redistribution and renal excretion; clinically, effect duration is short (1-2 hours) due to rapid redistribution into bone and other tissues.
Potassium chloride is not metabolized; potassium is excreted primarily by the kidneys. Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, with insulin facilitating cellular uptake.
Calcium gluconate is not metabolized. It dissociates to release calcium ions, which are distributed in the body and excreted primarily via the kidneys. The gluconate moiety is metabolized via the Krebs cycle.
Potassium is primarily excreted renally (approximately 90%) via glomerular filtration and distal tubular secretion. Minor fecal elimination accounts for ~10%. Renal excretion is influenced by aldosterone, acid-base status, and potassium intake.
Primarily renal (calcium is filtered and reabsorbed); negligible biliary/fecal. >98% of body calcium is in bone; excretion is complex and homeostatically regulated.
Potassium is minimally protein-bound (<5%); binding proteins are not clinically significant as free ion is active.
Approximately 45% bound to albumin; remaining free ionized calcium is the active form.
Vd is approximately 0.5-0.7 L/kg (total body water). This reflects extensive distribution into intracellular compartments, where 98% of total body potassium resides.
0.6-1.0 L/kg (distributes into extracellular fluid and bone; increases with bone turnover).
Intravenous: 100%. Oral: Approximately 90% absorbed in the small intestine (bioavailability is high but absorption can be affected by gastrointestinal motility and formulation). The 0.075% solution is for IV use only.
IV: 100%; IM: poor and erratic (not recommended); oral: ~20-30% (limited by absorption and binding, not used for urgent hypocalcemia).
For GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use or use with extreme caution and frequent monitoring.
No specific dose adjustment for renal impairment; however, caution in severe renal failure (GFR <30 m L/min) due to risk of hypercalcemia. Monitor serum calcium closely.
In hepatic impairment (Child-Pugh Class B or C): initiate at 50% of typical dose and titrate based on serum potassium levels and electrocardiographic monitoring; no specific adjustment for Child-Pugh A.
No adjustment required for hepatic impairment.
0.5-1 m Eq/kg per day as a continuous intravenous infusion, not to exceed 0.5 m Eq/kg/hour; maximum daily dose 3 m Eq/kg; must be diluted in appropriate IV fluid such as dextrose 5%.
Neonates and infants: 100-200 mg/kg/dose (1-2 m L/kg of 10% solution) IV slowly, maximum 2 g; children: 1-2 g/dose IV, maximum 2 g. Dilute to 50 mg/m L (5% solution) for IV administration.
Start at low end of dosing range (e.g., 10-20 m Eq per day) with careful titration; monitor renal function and serum potassium closely due to age-related decline in glomerular filtration rate.
Start at lower end of dosing range (e.g., 1 gram IV) due to increased risk of hypercalcemia and potential underlying renal insufficiency. Monitor calcium levels and cardiac function.
None
No FDA black box warning.
Risk of hyperkalemia, especially in patients with renal impairment, adrenal insufficiency, or those receiving potassium-sparing diuretics,Monitor serum potassium levels and ECG during administration,Do not administer undiluted potassium chloride; must be diluted in appropriate solutions,Use with caution in patients with cardiac disease or conditions predisposing to hyperkalemia,Rapid infusion may cause hyperkalemia and cardiac arrest
Risk of hypercalcemia; monitor serum calcium levels closely during therapy.,Risk of cardiac arrhythmias, especially if administered too rapidly or in patients receiving digoxin.,Avoid extravasation; may cause severe tissue necrosis (treat with hyaluronidase).,Use caution in renal impairment, sarcoidosis, or history of renal calculi.,Concomitant use with thiazide diuretics may increase risk of hypercalcemia.
Hyperkalemia,Severe renal impairment with oliguria or anuria,Adrenal insufficiency (e.g., Addison's disease),Acute dehydration,Concurrent use with potassium-sparing diuretics or ACE inhibitors at high risk of hyperkalemia,Conditions causing extensive tissue breakdown (e.g., severe burns, crush injuries) as they may release intracellular potassium
Hypercalcemia,Severe renal failure (relative, use with caution),Patients with ventricular fibrillation (use during cardiopulmonary resuscitation may be indicated),Digoxin toxicity (relative; may exacerbate arrhythmias, use with extreme caution)
Avoid potassium-rich foods or supplements unless explicitly prescribed, as this IV already provides potassium. Consult your provider about dietary potassium intake if you are on this infusion. High-potassium foods include bananas, oranges, potatoes, spinach, and salt substitutes.
Avoid high-calcium foods (dairy, fortified cereals) if hypercalcemia is a concern; oxalate-rich foods (spinach, rhubarb) may reduce absorption; do not take within 2 hours of iron or tetracycline antibiotics.
Potassium chloride and dextrose are not known teratogens. No fetal risk at therapeutic doses. Inadequate data for first trimester, risk cannot be excluded. Second and third trimesters: safe when used as indicated.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; deficiency may cause fetal skeletal abnormalities, but supplementation at recommended doses is unlikely to increase risk of major malformations. High doses may cause maternal hypercalcemia; risk of fetal hypoparathyroidism, tetany, and seizures if maternal calcium acutely increased. No known teratogenicity.
Potassium and dextrose are normal components of breast milk. No M/P ratio available. Considered compatible with breastfeeding at therapeutic doses.
Excreted into breast milk; M/P ratio approximately 0.5. Considered compatible with breastfeeding in usual maternal doses. Monitor infant for signs of hypercalcemia if maternal doses are high.
No specific dose adjustment required for pregnancy. However, increased plasma volume and GFR in pregnancy may alter potassium and glucose homeostasis; monitor levels and adjust accordingly.
Pregnancy-induced physiologic changes (increased plasma volume, increased GFR, placental calcium transfer) may lower maternal calcium levels; monitor and adjust dose as needed to maintain normal serum calcium. Intravenous doses typically require similar mg/kg dosing as non-pregnant; oral dosing may require a slight increase (10-20%) to compensate for increased demands and excretion. No standardized adjustment; individualized based on serum calcium levels.
This is a hypotonic potassium solution (K+ 10 m Eq/L) used for maintenance and replacement in patients with hypokalemia who also require dextrose. Monitor serum potassium and glucose, especially in diabetics. Do not administer undiluted; always add to a compatible IV solution. Use with caution in patients with renal impairment, cardiac disease, or those on digoxin due to risk of hyperkalemia. Pain at the infusion site may occur; consider central line administration for concentrations >10 m Eq/100 m L.
Administer via slow IV push (1-2 m L/min) to avoid cardiac arrest; monitor ECG during infusion; do not mix with bicarbonate or phosphate solutions; extravasation causes tissue necrosis; use with caution in digitalis toxicity.
This medication is given through a vein (IV) to provide potassium and sugar to your body.,Tell your healthcare provider if you have any kidney problems, heart disease, or diabetes.,Report any pain, redness, or swelling at the IV site.,You may need regular blood tests to check your potassium and sugar levels.,Do not suddenly stop receiving this treatment without consulting your provider.
Report any pain, redness, or swelling at injection site immediately,Avoid taking calcium supplements or antacids containing calcium without consulting your doctor,Inform about any heart conditions, especially irregular heartbeat,May cause dizziness or fainting if infused too quickly
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Calcium gluconate provides exogenous calcium, which can counteract the calcium channel blocking effect of nimodipine. This reduces nimodipine's ability to inhibit calcium influx into vascular smooth muscle cells, potentially decreasing its antihypertensive and vasodilatory efficacy. Clinically, coadministration may lead to reduced nimodipine effectiveness in preventing cerebral vasospasm after subarachnoid hemorrhage."
"Sodium glycerophosphate, an organic phosphate source, can chelate calcium ions in the gastrointestinal tract, forming insoluble calcium phosphate complexes. This reduces the absorption of orally administered calcium gluconate, leading to lower serum calcium concentrations. Clinically, this may result in diminished efficacy of calcium supplementation, potentially exacerbating hypocalcemia in susceptible patients."
"Calcium gluconate chelates deferiprone in the gastrointestinal tract, forming a non-absorbable complex that reduces deferiprone's bioavailability. This results in decreased serum concentrations and diminished therapeutic efficacy of deferiprone, potentially leading to inadequate chelation of iron in patients with iron overload. Clinically, patients may experience suboptimal reduction of serum ferritin and increased risk of iron-related organ damage."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER vs CALCIUM GLUCONATE, answered by our medical review team.
POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER is a Electrolyte Supplement that works by Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular fluid composition, nerve conduction, muscle contraction, and acid-base balance. Dextrose 5% provides a source of calories and water for hydration, with dextrose being metabolized to carbon dioxide and water, supplying energy.. CALCIUM GLUCONATE is a Electrolyte Supplement that works by Calcium gluconate dissociates to provide calcium ions, which are essential for nerve impulse transmission, muscle contraction, cardiac function, and blood coagulation. It acts as a mineral electrolyte replenisher.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCONATE depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous administration at a rate not exceeding 10 m Eq/hour of potassium chloride; typical adult dose is 20-40 m Eq per day administered as an additive to dextrose 5% solution, titrated to serum potassium levels.. The standard adult dose of CALCIUM GLUCONATE is: Intravenous: 1-2 grams (10-20 m L of 10% solution) administered slowly over 5-10 minutes. May repeat based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER and CALCIUM GLUCONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. POTASSIUM CHLORIDE 0.075% IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Potassium chloride and dextrose are not known teratogens. No fetal risk at therapeutic doses. Inadequate data for first trimester, risk cannot be excluded. Second and third trimest. CALCIUM GLUCONATE is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies not available. Second/third trimesters: Calcium gluconate is a physiologic electrolyte; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.